ISPOR 2022

Sponsor

August 2022

Carelon Research is a proud sponsor of ISPOR 2022: the leading global conference for health economics and outcomes research. Visit us at Booth #500 (or virtually), connect with our experts, and see our latest research.

Both in-person and virtual conference registration include extended access to all session playback recordings as well as virtual posters and networking through June 17, 2022. For more information, please visit ispor.org .

WORKSHOP

Concurrent breakout session 5 | Tuesday, May 17 | 1:30–2:30 pm ET

219 | Best practices for causal study designs using real-world data

Discussion leader: Michael Grabner, PhD¹

Discussants: Nilesh Gangan, PhD¹, Susan dosReis, PhD²

¹Carelon Research, Wilmington, DE, USA
²University of Maryland School of Pharmacy, Baltimore, MD, USA

Carelon Research presentations

Carelon Research authors are indicated in bold.

Presentation	Session	Title	Authors	Affiliations
Poster Session 1 Monday, May 16 12:15 – 1:15 PM EDT	Clinical outcomes / diabetes / endocrine / metabolic disorders	CO30 \| Clinical experiences of type 2 diabetes (T2DM) patients initiating oral semaglutide	Dunn TJ¹, Swift C^1, Guesnier A¹, Noone J¹, Willey V²	¹Novo Nordisk Inc., Plainsboro, NJ, USA, ²Carelon Research, Wilmington, DE, USA
Poster Session 1 Monday, May 16 12:15 – 1:15 PM EDT	Methodological & statistical research / no additional disease & conditions / specialized treatment areas	MSR11 \| A step-by-step guide for causal study design when estimating treatment effects using real-world data	Hoffman S¹, Gangan N¹, Chen X², Smith JL¹, Tave A¹, Yang Y¹, dosReis S³, Grabner M¹	¹Carelon Research, Wilmington, DE, USA, ²Elevance Health, Indianapolis, IN, USA, ³University of Maryland School of Pharmacy, Baltimore, MD, USA
Poster Session 3 Tuesday, May 17 12:15 – 1:15 PM EDT	Clinical outcomes / diabetes / endocrine / metabolic disorders Top 5% Finalist for the ISPOR 2022 Research Presentation Awards	CO94 \| Changes in demographic and clinical characteristics of patients with type 2 diabetes (T2DM) initiating subcutaneous semaglutide	Dunn TJ¹, Swift C¹, Guesnier A¹, Noone J¹, Willey V²	¹Novo Nordisk Inc., Plainsboro, NJ, USA, ²Carelon Research, Wilmington, DE, USA
Poster Session 3 Tuesday, May 17 12:15 – 1:15 PM EDT	Economic evaluation / diabetes / endocrine / metabolic disorders	EE242 \| Economic burden among chronic kidney disease (CKD) patients with and without type 2 diabetes (T2D) in a commercially insured/Medicare advantage (MA) population in the united states (US)	Chung H¹, Thomas N¹, Willey V¹, Kong SX², Singh R², Farej R^2,, Williamson T²	¹Carelon Research, Wilmington, DE, USA, ²Bayer U.S. LLC, Whippany, NJ, USA
Poster Session 4 Tuesday, May 17 5:30 – 6:30 PM EDT	Real world data & information systems / no additional disease & conditions / specialized treatment areas	RWD106 \| Characterizing telehealth utilization from administrative claims in the US using a standardized definition	Avula R¹, Grabner M¹, Eshete B¹, Stanek E², Willey V¹	¹Carelon Research, Wilmington, DE, USA, ²Elevance Health, Inc., Indianapolis, IN, USA
Poster Session 5 Wednesday, May 18 9:00 – 10:00 AM EDT	Clinical outcomes / diabetes / endocrine / metabolic disorders Top 5% Finalist for the ISPOR 2022 Research Presentation Awards	CO158 \| A Comparison of the clinical and economic outcomes associated with short-acting bronchodilator modes of delivery among patients with chronic obstructive pulmonary disease (COPD)	Pham T¹, Chen X¹, Talavera M¹, Napier M¹, Willey V²	¹Elevance Health, Indianapolis, IN, USA, ²Carelon Research, Wilmington, DE, USA

Our Services

Our Products

Sponsor

219 | Best practices for causal study designs using real-world data

Carelon Research presentations

Ready to learn more? Let's connect.